Cutler Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-28,600
Closed -$2K 5674
2017
Q4
$2K Sell
28,600
-4,700
-14% -$52.5K ﹤0.01% 4300
2017
Q3
$24K Sell
33,300
-10,400
-24% -$108K ﹤0.01% 2982
2017
Q2
$3K Buy
43,700
+35,200
+414% +$651K ﹤0.01% 5391
2017
Q1
$2K Buy
+8,500
New +$188K ﹤0.01% 5664
2016
Q4
Sell
-30,500
Closed -$34K 7735
2016
Q3
$34K Buy
30,500
+9,300
+44% +$283K ﹤0.01% 2875
2016
Q2
$18K Sell
21,200
-37,400
-64% -$1.01M ﹤0.01% 3507
2016
Q1
$93K Buy
58,600
+27,900
+91% +$646K 0.01% 1691
2015
Q4
$94K Buy
+30,700
New +$1.04M 0.01% 1837

Cutler Group's ALDR Position: Q4 2019 in Review

Cutler Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,500 shares — an estimated $28K sold.

Cutler Group first reported a position in ALDR in Q4 2015 and held it in 11 quarters. The position peaked at $492K in Q2 2017. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

  • Cutler Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Cutler Group sold 1,500 Alder Biopharmaceuticals shares in Q4 2019, an estimated $28K.
  • Cutler Group first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 11 quarters.
  • Cutler Group's Alder Biopharmaceuticals position peaked at $492K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Cutler Group's 13F filing for Q4 2019, filed 6 Feb 2020.